Introduction
Partial thromboplastin time (PTT) is the time it takes for a patient's blood to form a clot as measured in seconds. It is used to measure the activity of the intrinsic pathway of the clotting cascade.PTT tests the function of all clotting factors except factor VII factor and factor XIII (fibrin stabilizing factor). PTTis commonly used in clinical practiceto monitor patient response to unfractionated heparin infusion, totargettherapeutic anticoagulation, and as part of a "coagulation panel" to help elucidate causes of bleeding or clotting disorders.[1][2][3][4]
Specimen Collection
Clinicians draw blood from the vein of a patient by standard phlebotomy technique. Blood is collected in a citrate-containing collection tube, usually light blue. The citrate binds calcium, inhibiting clotting in the tube. This allows for a whole blood sample and effective extraction of plasma for testing. For patients on continuous unfractionated heparin, infusion blood is drawn every 6 hours to facilitate dosing adjustments.
Procedures
The PTT test uses decalcified blood to prevent clotting in the tube before the test begins. In the lab, plasma is separated from cellular components by centrifuge. Calcium and activating substances are then added to the plasma to begin the intrinsic pathway of the coagulation cascade. The activating substances are kaolin, which activates the contact-dependent factor XII (hydrated aluminum silicate), and cephalin, which substitutes for platelet phospholipids. PTTis the number of seconds needed to form a clot. Although time can vary dueto laboratory specifics, the standard for a sample clot is 35 seconds.[5][6][7][8]
Indications
PTT is usually measured as part of a panel of coagulation studies including international normalizing ratio (INR) and prothrombin time (PT). INR and PT both measure the activity of the extrinsic clotting cascade. Different disorders, medications, and physiologic conditions cancause an increase in these results, guiding clinicians in the diagnosis or treatment of medical conditions.[9][10]Common indications to measure PTT include the following:
PreoperativeTesting
Routinely included in preoperative laboratories, this practice is now being called into question for otherwise healthy patients undergoing low-risk or elective surgery. The Choosing Wisely Campaign recommends against routine preoperative laboratories in non-cardiac surgery unless otherwise clinically indicated.
Unfractionated Heparin Monitoring
PTT is a blood test used to measure a patient's response totreatment with unfractionated heparin infusion. While PTT does not measure anticoagulation directly, it measures the effect on blood clotting. Measured in seconds to clot formation, normal PTT can vary based on the laboratory or institution; however, normal PTT is between 25 to 35. PTT ranges are used to classify heparin dosing schemes as low or high intensity and to ensure effective dosing. Based on the goal PTT the dose of heparin can be increased or decreased to achieve the desired effect. While protocols vary from institution to institution, the therapeutic PTT range for heparin is 60 to 100 seconds, with lower-intensity dosing in the range of 60 to 80 seconds.
Screening for Bleeding Disorders
Patients with a propensity for bleeding should undergo testing to determine the presence of a clotting disorder. For patients with deficiencies or defects of the intrinsic clotting cascade, the PTT will be elevated. Disorders with an elevated PTT include:
Hemophilia A (factor VIII deficiency)
Hemophilia B (factor IX deficiency)
Vitamin K deficiency (both PT and PTT are elevated)
Von Willebrand disease (PTT can be normal depending on the severity of disease)
Disseminated intravascular coagulation (DIC) will demonstrate elevations in PT, PTT, and bleeding time (BT) with a decrease in platelet count (PC)
In a patient with elevated PTT and no known reasonfor it, further evaluation and testing is warranted.
Potential Diagnosis
Diagnoses associatedwith an elevated PTT include:
Hemophilia A (Factor VIII deficiency)
Factor VIII deficiency characterizes Hemophilia A, also known as classical hemophilia. This produces an intrinsic coagulation pathway defect and thus elevated PTT on laboratory studies. It isan X-linked recessive bleeding disorder; thus, it is more commonly seen in males. However, about one-third of casesresult from a spontaneous genetic mutation. The treatment varies depending on the severity of the disease. Some patients are treated with desmopressinto stimulate the release of Von Willebrand factor (WVF) from endothelial cells, which is protective of factor VIII.
Hemophilia B (Factor IX deficiency)
Hemophilia B is an X-linked recessive bleeding disorder characterized by factor IXdeficiency. This produces an intrinsic coagulation pathway defect and thus elevated PTT on laboratory studies. Patients are usually identified by family history or after evaluation for prolonged bleeding time with dental procedures or minor injury. Unlike hemophilia A, desmopressinhas no benefit for these patients.
Vitamin K Deficiency
PT and PTT are elevated with severe deficiency.
Deficiency of vitamin K, a fat-soluble vitamin, causes decreased synthesis of factors II, VII, IX, X, and proteins C and S. Newborns are administered an injection or oral supplementation of vitamin K shortly after birth to prevent risk hemorrhagic disease of the newborn (HDN)fromthis fat-soluble vitamin deficiency. Oral supplementation of vitamin K reverses coagulopathy in 24 hours; intravenous formulation reverses coagulopathy in 6 hours.
Liver Disease
PT and PTT are elevated with severe disease.
In mild liver disease, only the PT will be elevated. With more severe disease, both the PT and PTT will be elevated due to decreased synthesis of vitamin K-dependent clotting factors, which include factor II, factor VII, factor IX, and factor X. Correct with fresh frozen plasma (FFP), not vitamin K.
Von Willebrand Disease (VWD)
PTT can be normal or elevated depending on the severity of the disease.
Von Willebrand disease is an autosomal dominant deficiency in functional VWF. VWFhas 2 functions: binding platelets to the endothelium and protecting Factor VIII. There are 3 types of Von Willebrand disease. Type 1 is the most common (85% of patients). In type 1 VWD, there is a deficiency of normal-functioning VWF. Type 2 is characterized by a decreased amount of VWFthat does not function properly. Type 3 is the least common and most severe; these patients have a total or near-total absence of WVF and low levels of factor VIII.
Disseminated Intravascular Coagulation (DIC)
DIC is characterized by elevations in PT, PTT, and bleeding time (BT) with a decrease in platelet count (PC). It is a consumptive coagulopathy with coagulation and clot lysis occurring simultaneously. Patients develop consumptive thrombocytopenia, hemolytic anemia, local tissue ischemia, and hemorrhage.
Normal and Critical Findings
Normal PTT values vary betweenlaboratories, but 25 to 35 seconds is considered normal.
Interfering Factors
PTT can be falsely elevated in the case of antiphospholipid antibody syndrome, in which the lupus anticoagulant antibody interferes with phospholipids used to induce in vitro coagulation. However, the lupus anticoagulant antibody causes a prothrombotic effect in vivo, resulting in recurrent thromboses that characterize antiphospholipid antibody syndrome.[11] Other conditions can cause PTT to be persistently elevated even with the use of plasma mixing studies, in which the plasma of a patient with coagulopathy is mixed with normal plasma. These conditions are typically characterized by acquired coagulation factor inhibitors, which are antibodies that either decrease the activity or promote the degradation and clearance of coagulation factors.[12]
Clinical Significance
PTTis commonly used in clinical practiceto monitor unfractionated heparin infusion totarget the therapeutic range ofanticoagulation and as part of coagulation panels to help elucidate causes of bleeding or clotting disorders. PTT tests the function of all clotting factors except VII and XIII (fibrin stabilizing factor).
References
- 1.
Roshan TM, Stein N, Jiang XY. Comparison of clot-based and chromogenic assay for the determination of protein c activity. Blood Coagul Fibrinolysis. 2019 Jun;30(4):156-160. [PMC free article: PMC6594720] [PubMed: 31058653]
- 2.
Liu J, Liu Y, Liu S, Zhang Q, Zheng J, Niu Y, Wang X. Hypocoagulation induced by broad-spectrum antibiotics in extensive burn patients. Burns Trauma. 2019;7:13. [PMC free article: PMC6485059] [PubMed: 31058197]
- 3.
Macielak S, Burcham P, Whitson B, Abdel-Rasoul M, Rozycki A. Impact of anticoagulation strategy and agents on extracorporeal membrane oxygenation therapy. Perfusion. 2019 Nov;34(8):671-678. [PubMed: 31057056]
- 4.
Arnouk S, Altshuler D, Lewis TC, Merchan C, Smith DE, Toy B, Zakhary B, Papadopoulos J. Evaluation of Anti-Xa and Activated Partial Thromboplastin Time Monitoring of Heparin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Support. ASAIO J. 2020 Mar;66(3):300-306. [PubMed: 31045921]
- 5.
Sumislawski JJ, Christie SA, Kornblith LZ, Stettler GR, Nunns GR, Moore HB, Moore EE, Silliman CC, Sauaia A, Callcut RA, Cohen MJ. Discrepancies between conventional and viscoelastic assays in identifying trauma-induced coagulopathy. Am J Surg. 2019 Jun;217(6):1037-1041. [PMC free article: PMC6867692] [PubMed: 31029284]
- 6.
Lasne D, Pouplard C, Nougier C, Eschwege V, Le Cam duch*ez V, Proulle V, Smahi M, Harzallah I, Voisin S, Toulon P, Sobas F, Galinat H, Flaujac C, Ternisien C, Jeanpierre E., groupe d'études de la biologie des maladies hémorragiques du Groupe français d'études de l'hémostase et la thrombose. [Factor VIII assays in treated hemophilia A patients]. Ann Biol Clin (Paris). 2019 Feb 01;77(1):53-65. [PubMed: 30799298]
- 7.
Pouplard C, Jeanpierre E, Lasne D, Le Cam duch*ez V, Eschwege V, Flaujac C, Galinat H, Harzallah I, Proulle V, Smahi M, Sobas F, Ternisien C, Toulon P, Voisin S, Nougier C., groupe d’études de la biologie des maladies hémorragiques du Groupe français d’études de l’hémostase et la thrombose. [Factor IX assays in treated hemophilia B patients]. Ann Biol Clin (Paris). 2019 Feb 01;77(1):41-52. [PubMed: 30799297]
- 8.
Shaydakov ME, Sigmon DF, Blebea J. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 10, 2023. Thromboelastography. [PubMed: 30725746]
- 9.
St Pierre BP, Edwin SB. Assessment of Anticoagulation in Patients Receiving Ultrasound-Assisted Catheter-Directed Thrombolysis for Treatment of Pulmonary Embolism. Ann Pharmacother. 2019 May;53(5):453-457. [PubMed: 30378437]
- 10.
Loizou E, Mayhew DJ, Martlew V, Murthy BVS. Implications of deranged activated partial thromboplastin time for anaesthesia and surgery. Anaesthesia. 2018 Dec;73(12):1557-1563. [PubMed: 30315725]
- 11.
Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, Salmon JE, Shoenfeld Y, Shovman O, Hunt BJ. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018 Jan 25;4:18005. [PubMed: 29368699]
- 12.
Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, Morfini M, Santagostino E, Rocino A., AICE Working Group. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus. 2015 Jul;13(3):498-513. [PMC free article: PMC4614303] [PubMed: 26192778]
Disclosure: Kaitlyn Rountree declares no relevant financial relationships with ineligible companies.
Disclosure: Zachary Yaker declares no relevant financial relationships with ineligible companies.
Disclosure: Peter Lopez declares no relevant financial relationships with ineligible companies.
